Infinium Pharmachem Ltd (INFINIUM) — shareholding pattern, promoter holding, financials and share price
About Infinium Pharmachem Ltd (INFINIUM)
Infinium Pharmachem Ltd operates in the Pharmaceuticals industry, within the Healthcare sector. It trades on the NSE as INFINIUM and on the BSE under scrip code 78690. Its ISIN is INE0MRE01011.
Incorporated in 2003, Infinium Pharmachem Ltd manufactures and sells Iodian based Pharmaceutical Intermediates [1]
Infinium Pharmachem Limited specializes in the manufacturing of iodine-based pharmaceutical intermediates, catering to diverse industries such as pharmaceuticals, biotechnology, and specialty chemicals.
The company is strategically expanding its iodine value chain by venturing into the contrast media segment, aiming for substantial revenue from sales beginning FY26, and targeting Rs 300 Cr in revenue in 3-5 years.
Listed peers in Pharmaceuticals: Valiant Laboratories Ltd, Medicamen Biotech Ltd, Medico Remedies Ltd, Trident Lifeline Ltd, Everest Organics Ltd, BDH Industries Ltd.
Valuation & Returns
10 Jul 2026At ₹205.05 a share on 10 Jul 2026, Infinium Pharmachem Ltd (INFINIUM) was valued at a price-to-earnings ratio of 26.29x against an industry P/E of 36.41x and a price-to-book of 2.64x on a book value of ₹77.68 per share. Solomo computes return on equity of 10.04% and return on capital employed of 16.02% from filed results.
- P/E
- 26.29x
- Industry P/E
- 36.41x
- P/B
- 2.64x
- EPS (TTM)
- ₹7.8
- Book value / share
- ₹77.68
- ROE
- 10.04%
- ROCE
- 16.02%
- ROA
- 8.12%
- Debt / equity
- 0x
- Dividend yield
- 0%
- EBITDA margin
- 12.5%
- 52-week range
- ₹189.4 – ₹297
Ratios are computed from filed results and the last recorded price. Not investment advice.
Financial Performance
Mar 2026In the year ended Mar 2026, Infinium Pharmachem Ltd (INFINIUM) reported revenue of ₹190 crore, net profit of ₹14 crore and earnings per share of ₹7.8. That compares with revenue of ₹156 crore and net profit of ₹8 crore in Mar 2025. Figures are consolidated, as filed with the exchanges.
In the quarter ended Mar 2026, revenue was ₹106 crore and net profit ₹8 crore (consolidated).
| Metric | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 |
|---|---|---|---|---|---|
| Revenue (₹ cr) | 99 | 114 | 136 | 156 | 190 |
| Net profit (₹ cr) | 7 | 10 | 12 | 8 | 14 |
| EPS (₹) | 30.55 | 9.3 | 8.12 | 5.23 | 7.8 |
| Measure | 5Y | 3Y | 1Y |
|---|---|---|---|
| Sales growth | 30.60% | 22.74% | 14.78% |
| Profit growth | 52.76% | 15.45% | -31.83% |
| Stock price CAGR | - | 14% | -26% |
Ownership Summary
Mar 2026As of Mar 2026, promoters hold 64.91% of Infinium Pharmachem Ltd (INFINIUM). Market capitalisation was ₹320 crore on 10 Jul 2026. Shareholding is filed quarterly with BSE and NSE; Solomo carries every filing back to Sep 2023.
Largest disclosed public shareholders in Mar 2026: ASHISH AGARWAL 4.62%, ASHISH KACHOLIA 4.62%, DIPEN BABULAL DOBARIYA 1.61%, VINITKUMAR MAHESHKUMAR DOBARIYA 1.61%. Only stakes above the 1% disclosure threshold are named in filings.
| Quarter | Promoter | Pledged | FII | DII | Public |
|---|---|---|---|---|---|
| Mar 2026 | 64.91% | - | - | - | - |
| Sep 2025 | 59.91% | - | - | - | - |
| Mar 2025 | 65.24% | - | - | - | - |
| Sep 2024 | 73.05% | - | - | - | - |
| Mar 2024 | 73.05% | - | - | - | - |
| Sep 2023 | 73.05% | - | - | - | - |